Related Experiment Videos
Comorbidity as a prognostic factor in small cell lung cancer
Tanseli Efeoglu Gonlugur1, Ugur Gonlugur
1Sivas State Hospital, Department of Chest Diseases, Sivasiseases, Sivas, Turkey. tefeoglu@gmail.com
Tumori
|December 16, 2006
Summary
Prognostic factors significantly impact small cell lung cancer (SCLC) outcomes. Comorbidity, extensive chemotherapy, and treatment response are key predictors of survival in SCLC patients.
Area of Science:
- Oncology
- Pulmonology
- Clinical Research
Background:
- Small cell lung cancer (SCLC) has a generally poor prognosis.
- Numerous factors can influence treatment response and survival in SCLC patients.
Purpose of the Study:
- To identify prognostic factors affecting therapy response and survival in SCLC.
- To analyze pretreatment and treatment-related factors influencing SCLC patient outcomes.
Main Methods:
- Retrospective analysis of 90 SCLC patients.
- Evaluation of 32 pretreatment and 3 treatment-related prognostic factors.
- Univariate analysis and Cox multivariate regression modeling were employed.
Main Results:
- Median survival was 7 months, with a 1-year survival rate of 20%.
- Univariate analysis identified gender, comorbidity, thoracic irradiation, chemotherapy cycles (>3), chemotherapy response, and performance status as significant.
- Cox model revealed comorbidity, >3 chemotherapy cycles, and chemotherapy response as the only significant independent prognostic factors.
Conclusions:
- SCLC prognosis remains poor.
- Comorbidity is a critical factor that should be incorporated into future prognostic models for SCLC.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...